SEC Filing Summary
Filing identity: The supplied Form 10-Q is for Brooks Automation, Inc., not Azenta, Inc. It covers the fiscal quarter and nine-month period ended June 30, 2011, filed August 4, 2011. The financial statements are unaudited and amounts are generally in thousands, except per-share data.
Business Context and Reporting Period
Brooks provided automation, vacuum, instrumentation, and support solutions, primarily to semiconductor equipment customers. Semiconductor-related revenue represented approximately 80% of revenue for the first nine months of fiscal 2011. Reportable segments were Brooks Product Solutions, Brooks Global Services, and Contract Manufacturing.
The company acquired RTS Life Science Limited on April 1, 2011, and sold its extended factory contract manufacturing business on June 28, 2011. Segment reporting was reorganized beginning in the third quarter of fiscal 2011, with prior periods reclassified where applicable.
Key Financial Metrics
| Metric | Three months ended June 30, 2011 | Three months ended June 30, 2010 | Nine months ended June 30, 2011 | Nine months ended June 30, 2010 |
|---|---|---|---|---|
| Revenue | $186.1 million | $156.8 million | $557.2 million | $411.3 million |
| Gross profit | $57.0 million | $45.9 million | $176.0 million | $111.1 million |
| Gross margin | 30.6% | 29.3% | 31.6% | 27.0% |
| Operating income | $22.2 million | $16.5 million | $72.6 million | $24.7 million |
| Net income attributable to Brooks | $66.2 million | $16.6 million | $116.3 million | $34.8 million |
| Diluted EPS | $1.02 | $0.26 | $1.79 | $0.54 |
| Cash flow from operations | Not separately provided | Not separately provided | $67.2 million | $17.9 million |
| EBITDA | $73.2 million | $20.9 million | $133.1 million | $45.8 million |
Third-quarter revenue increased 18.7% year over year, while nine-month revenue increased 35.4%. Product revenue was $166.7 million in the quarter and $502.8 million year to date; services revenue was $19.5 million and $54.4 million, respectively.
At June 30, 2011, cash and cash equivalents were $133.1 million, restricted cash was $0.8 million, and marketable securities totaled $148.5 million, for aggregate cash, restricted cash, and marketable securities of approximately $282.4 million. Total current assets were $384.9 million versus current liabilities of $90.2 million. The filing does not report outstanding borrowings or traditional debt; interest expense was only $39,000 for the nine-month period.
Total assets were $626.4 million and total equity was $514.0 million at June 30, 2011. Accounts receivable were $82.5 million and inventories were $93.5 million.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven primarily by higher semiconductor capital-equipment shipments. Product Solutions revenue increased 24.9% in the quarter and 42.8% year to date; Global Services revenue increased 24.5% and 17.4%, respectively.
- Gross margin improved 130 basis points in the quarter and 460 basis points year to date, primarily from better absorption of factory and service overhead at higher volumes.
- Operating income increased 34.2% in the quarter and 194.4% year to date. Research and development expense increased to $10.0 million in the quarter and $28.4 million year to date, while SG&A increased to $24.7 million and $74.4 million, respectively.
- Net income benefited materially from the $45.0 million pretax gain on the sale of the Contract Manufacturing business. The transaction generated $75.7 million of cash proceeds during the nine-month period, with an estimated additional $2.5 million working-capital adjustment expected in the fourth quarter.
- The prior-year periods included a $7.8 million gain from the sale of intellectual property rights and a $2.2 million nine-month income tax benefit, including a $3.9 million alternative-minimum-tax refund. These items reduced comparability.
- Cash and cash equivalents increased $73.3 million from September 30, 2010, despite $67.2 million of net purchases of marketable securities, $4.2 million of capital expenditures, and $3.4 million spent on the RTS acquisition.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expected revenue for the quarter ending September 30, 2011 to decline from June-quarter levels because of the Contract Manufacturing divestiture, which contributed $42.3 million of June-quarter revenue, and softness in semiconductor-equipment demand. Acquisitions and growth outside semiconductors were expected to partially offset the decline.
- Management expected research and development spending to increase in the near term as it invested in product enhancements and non-semiconductor markets.
- On July 25, 2011, Brooks acquired Nexus Biosystems for $79.0 million plus $6.8 million of acquired unrestricted cash and assumed or paid a $6.0 million obligation to former owners of a business acquired by Nexus.
- The board declared an $0.08-per-share dividend payable September 30, 2011, totaling approximately $5.3 million. Future dividends remained discretionary.
- The company maintained a full valuation allowance against net deferred tax assets. It stated that up to $5.1 million of unrecognized tax benefits could be recognized within twelve months, including approximately $3.8 million anticipated in the fourth quarter of fiscal 2011, subject to audits and statute expirations.
- A settlement relating to former executive stock-option litigation produced $1.3 million of proceeds, with 50% recorded as income. A further approximately $4.0 million of income, inclusive of $0.7 million already recognized, could be recorded if the related SEC and court approvals became final.
- Key risks included semiconductor-industry cyclicality, softness in customer demand, possible supply disruptions from Japanese suppliers following natural disasters, acquisition integration risk, foreign-currency exposure, and potential impairment of goodwill or acquired intangible assets.
- The company had approximately $1.1 million of letters of credit outstanding and believed available resources were adequate for planned working capital and capital expenditures for the following twelve months. Longer-term liquidity remained subject to market conditions and acquisition requirements.
- Three customers each represented more than 10% of revenue in both the quarter and nine-month period, indicating customer-concentration risk.
Most Important Facts to Verify
- Confirm that this filing corresponds to the intended issuer: the source identifies Brooks Automation, Inc., while the request identifies Azenta, Inc.
- Separate recurring operating performance from the $45.0 million Contract Manufacturing divestiture gain, litigation income, and other unusual items when assessing earnings quality.
- Assess the effect of the Contract Manufacturing sale on post-June revenue, margins, customer relationships, supply agreements, and segment comparability.
- Review the Nexus acquisition, including purchase accounting, integration execution, assumed obligations, and its effect on liquidity after June 30, 2011.
- Evaluate exposure to semiconductor cyclicality, Japanese supply-chain disruption, customer concentration, and foreign-currency movements.
- Reconcile cash generation with working-capital needs, marketable-security investments, dividend payments, and future acquisition spending.
- Monitor the deferred-tax valuation allowance and potential tax-benefit recognition, as well as the pending SEC-related settlement and possible additional litigation income.